Compare American Homes 4 Rent Class A (AMH) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Ascendis Pharma A/S — how do they compare? American Homes 4 Rent Class A trades at $33.78 (market cap $12.28B), while Ascendis Pharma A/S trades at $255.85 (market cap $16.67B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| AMH | ASND | |
|---|---|---|
Market Cap | $12.28B | $16.67B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $277.18 |
52-Week Low | $27.38 | $189.74 |
Enterprise Value | $17.35B | $17.04B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH trades at $34.13, down 1.44% on the day, with a bullish technical signal from moving averages and a consensus price target of $36.45. The company reported strong Q2 2026 earnings, beating FFO and revenue estimates, and raised full-year guidance. Revenue grew to $1.85B in 2025, with net income margin improving to 25.53%. A dividend of $0.33 per share is scheduled for payment on June 30, 2026.
Outlook is positive with consistent earnings beats and raised guidance, but risks include high debt levels and regulatory impacts from new housing legislation. Institutional sentiment remains supportive with no sell ratings among analysts.
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
